Center-Authored Papers

Filters: Author is Atkins, Michael B  [Clear All Filters]
2017
Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA et al..  2017.  Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.. The Lancet. Oncology. Abstract
2015
Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH et al..  2015.  Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Compl. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
McDermott DF, Cheng S-C, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS et al..  2015.  The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(3):561-8. Abstract
Weber JS, Yang JC, Atkins MB, Disis ML.  2015.  Toxicities of Immunotherapy for the Practitioner.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
2008
Korn EL, Liu P-Y, Lee SJ, Chapman J-AW, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA et al..  2008.  Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(4):527-34. Abstract